Krystal Biotech

Krystal Biotech, based in Pittsburgh, PA, is a commercial-stage company dedicated to developing genetic medicines aimed at addressing severe, life-threatening, or rare diseases with limited or no approved therapies. Their flagship product, VYJUVEK, is the first and only redosable gene therapy specifically designed for the treatment of dystrophic epidermolysis bullosa.

With an extensive pipeline of promising genetic therapies, Krystal's mission is to correct the root causes of debilitating genetic conditions. Utilizing a clinically-proven platform based on a modified and engineered HSV-1 vector, the company is committed to advancing innovative solutions in the field of genetic medicine.

Generated from the website